[Sucralfate (Ulcogant). The mechanism of action of a cytoprotective agent].
The new antiulcer drug sucralfate is characterized by a multiple mode of action. Its predominant feature is a protection of the mucosa from endogenous and exogenous noxious agents. These cytoprotective properties result from a locally formed layer covering ulcers and erosions which inhibits the diffusion of H-ions and pepsin to the damaged mucosa. This layer is also stable against exogenous substances with deleterious effects on the mucosa like alcohol and salicylates. Furthermore, sucralfate binds pepsin and bile acids. Recently, a stimulating effect of sucralfate on the release of prostaglandins and the regeneration of epithelial cells in the gastric mucosa was demonstrated. There is no influence of sucralfate on the production of gastric juice and pH. Since sucralfate is minimally absorbed it is a safe and well tolerated drug.
D000327:Adsorption; D000535:Aluminum / Q000627:therapeutic use*; D000818:Animals; D001626:Bethanechol Compounds / Q000009:adverse effects; D001647:Bile Acids and Salts / Q000009:adverse effects; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D000431:Ethanol / Q000009:adverse effects; D005753:Gastric Mucosa / Q000187:drug effects; D005756:Gastritis / Q000517:prevention & control*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008564:Membrane Potentials / Q000187:drug effects; D010418:Pentagastrin / Q000009:adverse effects; D010434:Pepsin A / Q000009:adverse effects; D051381:Rats; D013392:Sucralfate
D001626:Bethanechol Compounds; D001647:Bile Acids and Salts; D000431:Ethanol; D013392:Sucralfate; D000535:Aluminum; D010434:Pepsin A; D010418:Pentagastrin
Sucralfat (Ulcogant) Der Wirkmechanismus eines Zytoprotektivums.